Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
AbbVie announced completion of its Capstan acquisition on August 19, 2025, adding a targeted LNP platform for RNA delivery and in vivo cell engineering. This historical ownership event explains the company relationship. Candidate-stage descriptions in that release should be read at their original date, not as a current trial update.
The 2022 study delivered CAR-encoding mRNA with CD5-targeted lipid nanoparticles, generating transient CAR T cells in mice. The abstract reports reduced cardiac fibrosis and improved function after injury. This is preclinical evidence, not human efficacy.
This 2020 study added a SORT component to lipid nanoparticles to alter tissue targeting and deliver mRNA or CRISPR cargoes. It provides preclinical evidence for extrahepatic delivery, rather than proof of human tissue targeting or clinical benefit.
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.